Investigating the Use of Topical Ruxolitinib in Chronic Hand Eczema
Significantly more patients who applied ruxolitinib cream 1.5% (Opzelura, Incyte) twice daily achieved Investigator’s Global Assessment-Chronic Hand Eczema (IGA-CHE) treatment success at Week 16 when compared to patients who received vehicle. Linda Stein Gold, MD, Director of Dermatology Clinical Research at Henry Ford Health System in Detroit, MI, reviews the data that was presented at the 2024 Fall Clinical Dermatology Conference in Las Vegas, NV, for the first time.
